Evidence map›Paper›PMID 39828291›Full record

ArticleBMJ case reports2025

Petroclival meningioma regression after combined oestrogen and nomegestrol acetate interruption.

Julie Lebeau, Louis Deprez, Axelle Pintiaux, Gilles Reuter

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Julie LebeauCHU de Liège, Liege, Belgium.
Louis DeprezRadiodiagnostics, CHU de Liège, Liege, Belgium.
Axelle PintiauxGynaecology and Obstetrics, CHU de Liège, Liege, Belgium.
Gilles ReuterNeurosurgery, CHU de Liege Hospital Sart Tilman, Liege, Belgium gilles.reuter@chuliege.be.ORCID http://orcid.org/0000-0002-7484-3110

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Meningioma regression after progestin treatment interruption is already established. Zoely is a combined oral contraceptive including oestradiol and progestin (nomegestrol acetate). The effect of combined oestrogen with nomegestrol acetate on meningioma is currently unknown. We report the case of a woman in her early 50s under Zoely for 5 years who was diagnosed with a large petroclival meningioma. After cessation of Zoely, the patient showed clinical improvement and shrinkage of the tumour volume from 27.22 cm

Indexed as

EstrogensMegestrolMeningeal NeoplasmsMeningiomaNeoplasm Regression, SpontaneousNorpregnadienesFemaleHumansMagnetic Resonance ImagingMiddle AgedEstrogensMegestrolnomegestrol acetateNorpregnadienesContraceptionDrug therapy related to surgeryNeurooncology

Identifiers

PMID39828291
PMCPMC11751604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.